Clin2
NCT07241520Possibly a fitRecruiting

Testing SHPL-49 injection for recent stroke patients

Acute Ischemic Stroke

Part of Brain & nervous system, Heart & circulation clinical trials.

This trial tests a new medication, SHPL-49, given as an injection to people who have just had a stroke caused by a blood clot (ischemic stroke). It is for patients who are already receiving standard clot-busting treatment within 8 hours of symptoms starting. The study will see if adding this drug helps improve recovery.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
1,096 people
Ages
18 years to 80 years
Study type
Interventional

Who can take part

  • Aged 18 to 80 years old
  • Diagnosed with an acute ischemic stroke (clot-caused stroke) and treated with a clot-busting drug within 8 hours of symptoms starting
  • Stroke symptoms are moderate to moderately severe (NIHSS score between 5 and 22) before clot-busting treatment
  • Able to walk independently and care for yourself before the stroke (mRS score 0 or 1)
  • No severe kidney, liver, or heart problems, and no history of certain heart conditions like atrial fibrillation

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07396337Recruiting· Phase 2
Study of QHRD106 injection for acute ischemic stroke

This trial tests an investigational drug, QHRD106, given as an injection for people who have had a moderate-to-severe acute ischemic stroke. It aims to see if the drug can help recovery when given within 24 hours after the stroke starts, and it is for patients who are not receiving standard clot-busting treatment.

Nanjing, Jiangsu
NCT07205328Recruiting· Phase 2
Testing MT200605 for acute ischemic stroke

This trial tests whether MT200605 can help people who recently had an ischemic stroke (a type of stroke caused by a blocked blood vessel). The drug is given within 24 hours of symptoms starting, and you may join even if you received clot-busting treatment already.

Beijing, Beijing Municipality
NCT07739160Not yet recruiting· Phase 2
Study of HRS-4029 for acute ischemic stroke

This trial tests a new drug, HRS-4029, given within 3 hours of an ischemic stroke (a stroke caused by a blocked blood vessel). The goal is to see if the drug helps improve recovery.

Beijing, Beijing Municipality
NCT07201688Recruiting· Phase 3
Extending the window for stroke clot-busting drug

This trial tests a clot-dissolving medication called rhTNK-tPA for people who had a stroke 4.5 to 24 hours ago. It aims to help those with certain types of blockages in the brain who are still having moderate to severe symptoms.

Puyang, Henan
NCT06663631Recruiting· Phase 1
Hibernation-like therapy for stroke recovery after clot removal

This trial tests if a hibernation-like therapy can improve recovery after a stroke caused by a large blood clot in the brain. It is for people who are having a stroke and are scheduled for a procedure to remove the clot.

Linyi, Shandong
NCT07469293Not yet recruiting· Phase 3
Study of artery-injected tenecteplase for stroke with medium vessel blockage

This trial tests a clot-busting drug called tenecteplase, given directly into the blocked artery, for people who have had a stroke caused by a medium-sized brain vessel blockage within the last 24 hours. It aims to see if this treatment is safe and effective in improving recovery.

Baise City, Guangxi

Hear when a new Acute Ischemic Stroke trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.